Press Releases

Atomwise Appoints Steve Worland, Ph.D. as Chief Executive Officer
Atomwise Appoints Steve Worland, Ph.D. as Chief Executive Officer

Proven Pharmaceutical Executive Brings Over 30 Years of R&D Experienceto Supercharge the Company’s Next Phase of Growth Seasoned Biotechnology Leader Mike Varney, Ph. D., Appointed as Lead Independent Director of the Board SAN FRANCISCO, CALIFORNIA, FEBRUARY 18, 2025 – Atomwise, a leader in leveraging machine learning and artificial intelligence (ML/AI) to advance small molecule drug […]


February 18, 2025

Atomwise Appoints Steve Worland, Ph.D. as Chief Executive Officer
Atomwise Appoints Steve Worland, Ph.D. as Chief Executive Officer

Proven Pharmaceutical Executive Brings Over 30 Years of R&D Experienceto Supercharge the Company’s Next Phase of Growth Seasoned Biotechnology Leader Mike Varney, Ph. D., Appointed as Lead Independent Director of the Board SAN FRANCISCO, CALIFORNIA, FEBRUARY 18, 2025 – Atomwise, a leader in leveraging machine learning and artificial intelligence (ML/AI) to advance small molecule drug […]


February 18, 2025

Press Release: Atomwise Publishes Results from 318-Target Study Showcasing AtomNet AI Platform’s Ability to Discover Structurally Novel Chemical Matter
Atomwise Publishes Results from 318-Target Study Showcasing AtomNet AI Platform’s Ability to Discover Structurally Novel Chemical Matter

San Francisco, CA – April 2, 2024 – Atomwise announced today results from the AIMS (Artificial Intelligence Molecular Screen) initiative that establish the AtomNet AI Platform as a viable alternative to high-throughput screening (HTS) and verify its ability to consistently discover structurally novel chemical matter. The landmark study applied AtomNet to 318 targets through collaborations […]


April 2, 2024

Press Release: Atomwise Announces Nomination of its First AI-Driven Development Candidate Focused on TYK2 Inhibition and Appoints Neely Mozaffarian, MD, PhD as Chief Medical Officer
Atomwise Announces Nomination of its First AI-Driven Development Candidate Focused on TYK2 Inhibition and Appoints Neely Mozaffarian, MD, PhD as Chief Medical Officer

SAN FRANCISCO–(BUSINESS WIRE)– Atomwise, a leader in using AI for small molecule drug discovery, today announced the nomination of its first AI-driven development candidate focused on TYK2 inhibition and the appointment of Neely Mozaffarian, MD, PhD as Chief Medical Officer. Dr. Mozaffarian brings over 25 years of immunology and clinical research experience to the role […]


October 5, 2023

Atomwise Appoints Gavin Hirst, Ph.D., as Chief Scientific Officer
Atomwise Appoints Gavin Hirst, Ph.D., as Chief Scientific Officer

Veteran drug hunter adds discovery expertise to technology-enabled biopharma company SAN FRANCISCO, Calif. — September 14, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced the appointment of Gavin Hirst, Ph.D., as Chief Scientific Officer. Dr. Hirst brings more than 30 years of expertise in drug discovery […]


September 14, 2022

Press Release: Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery
Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery

Agreement includes upfront payment of $20 million with the potential for $1 billion in milestone-based payments plus tiered royalties SAN FRANCISCO — August 17, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced that it has established a strategic and exclusive research collaboration with Sanofi that will […]

Leadership team additions
Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments

CSO, CFO, and GC added as technology-enabled pharma company bolsters growing management team and SAB SAN FRANCISCO, Calif. — January 25, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer. Additional management team appointments include Jonathan Barr […]


January 25, 2022